Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate.
A major determinant of maximal exercise capacity is the delivery of oxygen to exercising muscles. myo-Inositol trispyrophosphate (ITPP) is a recently identified membrane-permeant molecule that causes allosteric regulation of Hb oxygen binding affinity. In normal mice, i.p. administration of ITPP (0.5-3 g/kg) caused a dose-related increase in the oxygen tension at which Hb is 50% saturated (p50), with a maximal increase of 31%. In parallel experiments, ITPP caused a dose-related increase in maximal exercise capacity, with a maximal increase of 57 +/- 13% (P = 0.002). In transgenic mice with severe heart failure caused by cardiac-specific overexpression of G alpha q, i.p. ITPP increased exercise capacity, with a maximal increase of 63 +/- 7% (P = 0.005). Oral administration of ITPP in drinking water increased Hb p50 and maximal exercise capacity (+34 +/- 10%; P < 0.002) in normal and failing mice. Consistent with increased tissue oxygen availability, ITPP decreased hypoxia inducible factor-1alpha mRNA expression in myocardium. It had no effect on myocardial contractility in isolated mouse cardiac myocytes and did not affect arterial blood pressure in vivo in mice. Thus, ITPP decreases the oxygen binding affinity of Hb, increases tissue oxygen delivery, and increases maximal exercise capacity in normal mice and mice with severe heart failure. ITPP is thus an attractive candidate for the therapy of patients with reduced exercise capacity caused by heart failure.
Biolo
Andreia
A
Cardiovascular Section, Department of Medicine, Boston University Medical Center, and Myocardial Biology Unit, Boston University School of Medicine, Boston, MA 02115, USA.
Greferath
Ruth
R
Siwik
Deborah A
DA
Qin
Fuzhong
F
Valsky
Eugene
E
Fylaktakidou
Konstantina C
KC
Pothukanuri
Srinivasu
S
Duarte
Carolina D
CD
Schwarz
Richard P
RP
Lehn
Jean-Marie
JM
Nicolau
Claude
C
Colucci
Wilson S
WS
D000494:Allosteric Regulation / Q000187:drug effects; D000818:Animals; D017079:Exercise Tolerance / Q000187:drug effects*; D043802:GTP-Binding Protein alpha Subunits, Gq-G11 / Q000235:genetics; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006454:Hemoglobins / Q000187:drug effects* / Q000378:metabolism; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000235:genetics; D007295:Inositol Phosphates / Q000494:pharmacology* / Q000627:therapeutic use; D051379:Mice; D008822:Mice, Transgenic; D010100:Oxygen / Q000378:metabolism; D012333:RNA, Messenger; D016896:Treatment Outcome
D006454:Hemoglobins; C497443:Hif1a protein, mouse; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D007295:Inositol Phosphates; D012333:RNA, Messenger; C516441:inositol trispyrophosphate; D043802:GTP-Binding Protein alpha Subunits, Gq-G11; D010100:Oxygen